Skip to main content

Table 1 Clinical characteristics of the study subjects

From: The combination of nonthyroidal illness syndrome and renal dysfunction further increases mortality risk in patients with acute myocardial infarction: a prospective cohort study

Variables Normal
(n = 692)
NTIS
(n = 139)
Renal dysfunction (n = 304) Combined (n = 160) P value P value*
Age (years) 65 ± 13 70 ± 12 75 ± 9 77 ± 10 < 0.001 < 0.001
Male(n,%) 536 (77.5%) 78 (56.1%) 147 (48.4%) 97 (60.6%) < 0.001 0.001
Hypertension(n,%) 403 (58.2%) 83 (59.7%) 227 (74.7%) 107 (66.9%) < 0.001 0.112
Diabetes mellitus (n,%) 181 (26.2%) 46 (33.1%) 111 (36.5%) 61 (38.1%) 0.001 0.001
Smoking(n,%) 452 (65.5%) 82 (59.0%) 150 (49.3%) 81 (50.6%) < 0.001 0.083
Alcohol(n,%) 50 (7.3%) 5 (3.6%) 7 (2.3%) 6 (3.8%) 0.006 0.597
SBP (mmHg) 128 ± 22 123 ± 23 132 ± 24 127 ± 26 0.003 < 0.001
DBP (mmHg) 75 ± 13 70 ± 13 73 ± 13 72 ± 14 0.001 < 0.001
BMI (kg/m2) 24.24 ± 2.04 23.36 ± 2.53 23.55 ± 2.53 23.46 ± 2.66 < 0.001 0.03
WBC (×109/l) 8.64 ± 3.69 9.71 ± 4.90 8.30 ± 3.98 9.98 ± 4.91 < 0.001 < 0.001
Hb (g/l) 139 ± 15 129 ± 16 124 ± 17 116 ± 20 < 0.001 < 0.001
Alb (g/l) 41 ± 6 38 ± 6 40 ± 5 37 ± 6 < 0.001 0.001
CRP (mg/l) 3.4 (1.6–6.5) 10.0 (4.8–21.3) 5.1 (3.5–8.0) 18.2 (8.8–33.0) < 0.001 < 0.001
TG (mmol/l) 1.54 ± 0.91 1.37 ± 1.07 1.40 ± 0.80 1.30 ± 0.91 < 0.001 0.005
TC (mmol/l) 4.60 ± 1.15 4.64 ± 1.15 4.34 ± 1.14 4.24 ± 1.17 0.007 < 0.001
HDL-C(mmol/l) 1.05 (0.90–1.22) 1.05 (0.93–1.21) 1.06 (0.85–1.23) 1.03 (0.87–1.20) 0.361 0.245
LDL-C(mmol/l) 2.92 (2.34–3.55) 2.80 (2.23–3.55) 2.67 (2.09–3.44) 2.56 (2.02–3.25) < 0.001 0.547
FPG (mmol/l) 6.98 ± 3.30 7.95 ± 3.65 7.10 ± 3.31 7.60 ± 3.07 0.003 0.007
FT3(pmol/l) 4.05 ± 0.55 2.60 ± 0.47 3.88 ± 0.53 2.52 ± 0.46 < 0.001 < 0.001
FT4(pmol/l) 16.15 ± 2.23 15.26 ± 2.06 16.52 ± 2.30 15.17 ± 2.53 < 0.001 < 0.001
TSH(mU/l) 1.30 (0.75–2.12) 1.26 (0.57–1.94) 1.47 (0.98–2.29) 1.25 (0.59–1.84) < 0.001 0.004
sCr (μmol/l) 76 (65–88) 74 (60–89) 118 (102–142) 135 (109–178) < 0.001 < 0.001
eGFR(ml/min/1.73m2) 89.69 ± 29.58 86.77 ± 28.15 44.03 ± 12.90 39.84 ± 14.50 < 0.001 < 0.001
Antiplatelet agents(n,%) 446 (64.6%) 93 (66.9%) 180 (59.2%) 96 (60.0%) 0.241 0.491
β-blockers(n,%) 379 (55.0%) 77 (55.4%) 217 (71.4%) 110 (68.8%) < 0.001 0.005
LLDs (n,%) 462 (67.0%) 95 (68.3%) 158 (52.1%) 92 (57.5%) < 0.001 0.040
ACEIs/ARBs(n,%) 363 (52.6%) 89 (64.0%) 140 (46.2%) 70 (43.8%) 0.001 0.133
CCBs (n,%) 81 (11.7%) 12 (8.6%) 39 (12.8%) 19 (11.9%) 0.649 0.922
Diuretics(n,%) 492 (71.2%) 116 (83.5%) 210 (69.1%) 114 (71.3%) 0.014 0.873
Revascularization during the present hospitalization(n,%) 539 (77.9%) 98 (70.5%) 163 (53.6%) 68 (42.5%) < 0.001 < 0.001
Prior PCI or CABG (n,%) 24 (3.5%) 4 (2.9%) 6 (2.0%) 6 (3.8%) 0.604 0.622
Infarct type (NSTEMI n,%) 42 (6.1%) 11 (7.9%) 17 (5.6%) 12 (7.5%) 0.725 0.627
  1. Values are expressed as mean ± SD,median with interquartile range or percentages
  2. The p values were not adjusted for age and sex for the trend
  3. The p values* were adjusted for age and sex for the trend
  4. Revascularization included percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG)